Johnson & Johnson has submitted an application to the U.S. Food and Drug Administration for approval of its autoimmune drug nipocalimab, intended for the treatment of Myasthenia gravis, a chronic neuromuscular disease.
Johnson & Johnson has submitted an application to the U.S. Food and Drug Administration for approval of its autoimmune drug nipocalimab, intended for the treatment of Myasthenia gravis, a chronic neuromuscular disease.
